Evofem strengthens the intellectual property of Phexxi® with a new composition of matter patent from the USPTO

SAN DIEGO, June 30, 2022 /PRNewswire/ — Evofem BiosciencesInc., (Nasdaq: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company Notice of Allowance for patent application 16/738,868 entitled “Compositions and Methods for Improving the Efficacy of Contraceptive Microbicides” which covers the material composition of Phexxi® (lactic acid, citric acid, potassium bitartrate) and should provide protection until at least 2033.



With the issuance of this patent, in United StatesEvofem alone shall have the right to manufacture, have manufactured, market and sell for any commercial purpose the composition of matter making up Phexxi.


“We are delighted to receive this new patent, which further builds on our material protection composition and although already well protected by over 40 patents, this allocation further reinforces the investment Evofem has made in creating of Phexxi and provides it to women across United States,” said Saundra Pelletier, CEO of Evofem. “This patent grant is a clear nod to the innovation that Phexxi brings to contraception and a woman’s ability to protect herself against unwanted pregnancy.”


About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) develops and markets innovative products to address the unmet sexual and reproductive health needs of women, including hormone-free, female-controlled contraception and protection against chlamydia and gonorrhea. The company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free prescription vaginal contraceptive gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each sexual intercourse. The first data is expected in the second half of 2022 from phase 3 of registration EVOGUARD trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women, two potential new indications. Learn more at phexxi.com and evofem.com.


Phexxi® is a registered trademark of Evofem Biosciences, Inc.


Forward-looking statements
This press release contains “forward-looking statements”, within the meaning of the safe harbor for forward-looking statements provided for by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including , without limitation, statements regarding the expected timing of issuance of the new composition of matter patent for Phexxi. A variety of factors could cause actual results to differ materially from those discussed or implied by the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on such forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could adversely affect the value of the assets and businesses of Evofem Biosciences, are disclosed in the documents filed by the Company with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 10, 2022. All forward-looking statements are expressly qualified in their entirety by these factors . The Company undertakes no obligation to update forward-looking statements, except as required by law.


Evofem Biosciences contacts:


Media

jack hirschfield
Evofem Biosciences, Inc.
[email protected]
(512) 674-5163


Investor Relations

Amy Raskopf
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775




Quote See original content to download multimedia: https://www.prnewswire.com/news-releases/evofem-strengthens-phexxi-intellectual-property-with-new-composition-of-matter-patent-from-uspto-301578730 .html


SOURCEEvofem Biosciences, Inc.

Comments are closed.